The prevention trial DiaPrecise with Diamyd® clears first safety milestone
The first safety review in the ongoing DiaPrecise trial in individuals with Stage 1 and Stage 2 Type 1 Diabetes has been successfully completed by the independent Data Safety Monitoring Board (DSMB), following treatment of the initial three participants. The DSMB reported no safety concerns related to the injection procedure or investigational medicine, supporting continued subject enrollment. Additional participants are currently in the screening phase.“The DSMB’s green light following the first safety review is an important step forward in enabling early, personalized treatment of Type 1